Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Skin

Argireline

Also known as Acetyl hexapeptide-8 · Acetyl hexapeptide-3 · Argireline NP · Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2 · "Botox in a bottle" (marketing phrase) · AH-8

Not approved — research use onlyBLimited human dataWhat this means

Argireline is the trade name of acetyl hexapeptide-8, a cosmetic ingredient modelled on part of the SNAP-25 protein and marketed as a topical alternative to botulinum toxin; the small human studies located are mixed, including a double-blind split-face study that found no significant difference from the vehicle, and the proposed neuromuscular mechanism has not been demonstrated for it.

US status
Not approved — research use only
Evidence
Grade B
Half-life
Not located in the sources reviewed. Related work on cosmetic peptides reports rapid degradation in skin extracts, but no half-life for this peptide in humans was identified 11.
Class
Acetylated, C-terminally amidated synthetic hexapeptide; cosmetic ingredient derived from the SNAP-25 sequence
Studied in: Skin research
More
Log a sample
Dosing referenceCycle-length evidence
Unbranded reference vial illustrating Argireline; not an actual product
Research reference, not advice. No administration data. Amiravo sells nothing; some links are referrals.Read the full notice

Key takeaways

  • Argireline is the trade name for acetyl hexapeptide-8, a cosmetic ingredient, not a drug; cosmetic ingredients receive no FDA premarket approval and it is absent from FDA's 503A bulk substances list 1,9.
  • The human evidence located is small and mixed. A double-blind split-face study in 19 women found no statistically significant difference between the serum containing the peptide and the same serum without it, and its author concluded the effect was not demonstrated 3.
  • A small three-arm randomized trial in 21 women reported changes in some subjects with acetyl hexapeptide-3 cream and judged palmitoyl pentapeptide-4 to show more change over eight weeks; the authors called the sample inadequate for firm conclusions 4.
  • The SNARE-interference mechanism is inferred from sequence resemblance to SNAP-25. A 2025 review concluded that whether the peptide reaches neuromuscular junctions after topical application remains uncertain, and in a rat injection model it produced a collagen profile indistinguishable from saline 2,5.
  • The Cosmetic Ingredient Review panel's conclusion is bounded to concentrations up to 0.005%, with data judged insufficient above that 1.

Development stage

Where Argireline sits between laboratory work and regulatory approval.

  1. Preclinical
  2. Phase 1
  3. Phase 2
  4. Phase 3 (current)
  5. Approved

Stage comes from the regulatory record and ClinicalTrials.gov studies naming the compound (for compounds approved nowhere, only completed trials or trials with posted results count) (checked 2026-10-24). A registered trial is not a result.

Mechanism of action

Acetyl hexapeptide-8 is a six-residue peptide, Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2, whose sequence corresponds to part of the N-terminal region of SNAP-25 8. The commercial rationale is that it competes within the SNARE complex that mediates vesicular acetylcholine release at the neuromuscular junction, so that topical application reduces contraction of the mimetic muscles producing expression lines 2,6.

Evidential basis for the mechanism

Reviews describe the peptide as a "botox-like" or botulinum toxin mimetic while stating that the underlying biology, and in particular its capacity to inhibit muscle contraction after topical application, remains incompletely understood 2,6. In a rat flap model in which the peptide was injected subdermally rather than applied topically, it produced a dermal collagen type I/III profile indistinguishable from saline control and no detectable tissue-level effect, while botulinum toxin type A shifted collagen composition 5.

Delivery

The peptide is hydrophilic and comparatively large, which the 2025 permeability review identifies as the central limitation: oil-in-water and water-in-oil-in-water emulsion strategies have been explored, but whether enough peptide reaches a relevant depth is unresolved 2. Work on another cosmetic pentapeptide in excised skin found rapid proteolytic degradation and no permeation into the receptor compartment, illustrating the general problem for peptides of this class 11.

Research overview

Human research

The studies located are small. In a double-blind, split-face study, 19 women applied a triple-hyaluronic-acid serum containing the peptide to one side of the face and the same serum without it to the other for four weeks; instrument-measured wrinkle scores and the device's skin-age output fell slightly on both sides, with no statistically significant difference between sides (p = 0.829 for wrinkle score), and the author concluded the peptide's effect was not demonstrated and that it is not an alternative to botulinum toxin 3. In a double-blind randomized trial, 21 Indonesian women aged 26 to 55 with crow's feet used acetyl hexapeptide-3 cream, palmitoyl pentapeptide-4 cream or placebo for eight weeks with corneometry, tewametry, cutometry, photography and a grading scale; the authors reported improvement in several subjects in both active arms, judged the palmitoyl pentapeptide-4 arm to show more change, and called for larger and longer study 4. A 2026 ex vivo and clinical report tested a serum containing the peptide together with dipeptide diaminobutyroyl benzylamide diacetate and gluconolactone, so no effect can be attributed to the peptide alone 12. A separate analysis of United States Google search volume from 2013 to 2023 documents rising public interest, not efficacy 7.

Animal research

In 40 female Wistar rats allocated to saline, botulinum toxin type A, the peptide, or the combination, subdermal injections were given before raising a caudally based McFarlane flap. Flap survival did not differ between groups; botulinum-containing groups showed lower type I and higher type III collagen, while the peptide alone produced a profile indistinguishable from control, which the authors described as no detectable tissue-level effect under the tested conditions 5.

In-vitro research

No mechanistic in vitro study demonstrating SNARE interference by this peptide was identified in the sources reviewed; reviews describe the mechanism as a premise rather than a demonstrated finding 2,6. Permeability work on cosmetic peptides generally reports rapid degradation in skin and poor passage through full-thickness skin 11.

Key studies

  1. Henseler, GMS Interdiscip Plast Reconstr Surg DGPW (2023)
    Double-blind, split-face comparison of a hyaluronic acid serum with and without the peptide over four weeks, with instrument imaging
    Model: Humans (19 women)

    Wrinkle scores fell slightly on both sides with no statistically significant difference between the side receiving the peptide and the side receiving the serum alone; the author concluded the peptide's effect was not demonstrated.

  2. Aruan et al., J Clin Aesthet Dermatol (2023)
    Double-blind randomized three-arm trial over eight weeks with instrumental and photographic assessment
    Model: Humans (21 Indonesian women aged 26 to 55 with crow's feet)

    Improvement was reported in several subjects in both peptide arms; the authors judged the palmitoyl pentapeptide-4 arm to show more change than acetyl hexapeptide-3 and placebo, and described the study as preliminary.

  3. Acuner et al., Aesthetic Plast Surg (2026)
    Four-group controlled animal experiment with picrosirius red collagen typing and Substance P immunohistochemistry
    Model: Animals (40 female Wistar rats, McFarlane flap model)

    The peptide alone produced a collagen type I/III profile indistinguishable from saline control and no detectable tissue-level effect; flap survival did not differ between groups.

  4. Zdrada-Nowak et al., Int J Mol Sci (review) (2025)
    Narrative review of permeability and efficacy
    Model: Not applicable

    Concluded that low skin penetration limits bioavailability, that whether the peptide reaches neuromuscular junctions is uncertain, and that the mechanisms behind reported cosmetic changes are incompletely understood.

  5. Cosmetic Ingredient Review Expert Panel, Int J Toxicol (2025)
    Expert panel safety assessment of published and submitted data
    Model: Not applicable (cosmetic ingredient safety review)

    Concluded the ingredient raised no safety concern in cosmetics at concentrations up to 0.005% in present practices of use, and that available data are insufficient to reach that conclusion at higher concentrations.

  6. Olsson et al., JMIR Dermatol (2024)
    Longitudinal analysis of United States Google relative search volume, 2013 to 2023
    Model: Not applicable (internet search volume)

    Searches for "Argireline" and "Botox in a Bottle" rose sharply in 2022 while remaining below "Botox"; this documents public interest, not efficacy.

Published adverse-event data

Reported in the cited trials or product labels. Frequencies apply to the stated population and do not transfer to other settings.

Emerging safety signals

  • The Cosmetic Ingredient Review Expert Panel's 2025 conclusion is bounded: the ingredient was judged to raise no safety concern in cosmetics at concentrations up to 0.005% in present practices of use, with available data judged insufficient above that concentration 1. 1 (2025)
  • In the split-face human study, no significant adverse events, allergic reactions or skin irritation were reported over four weeks in 19 participants; the study was not designed or sized to detect uncommon events 3. 3 (2023)

What is not known: Whether topically applied acetyl hexapeptide-8 reaches neuromuscular junctions at all is unresolved, and no study demonstrating SNARE interference by this peptide was identified 2,5,6. The size of any wrinkle effect is uncertain: the one double-blind split-face comparison was null, the one three-arm randomized trial was small and described by its authors as preliminary, and other human data come from multi-ingredient products 3,4,12. No pharmacokinetic or half-life data in humans were identified 2,11. Safety above the concentration the Cosmetic Ingredient Review panel assessed is not established 1.

Background viewing

We haven't found a clinician video focused on Argireline yet. Meanwhile, this widely watched talk covers the science of aging in general. It does not discuss Argireline.

David Sinclair, PhD (Harvard Medical School) on the biology of aging
The Diary Of A CEO · 6.9M views · 2026

These creators are not affiliated with Amiravo and do not endorse Amiravo or any product linked on this site. Nothing here is medical advice. Video views counted on YouTube as of Oct 24, 2026.

Regulatory status

Status
A cosmetic ingredient, not an approved drug. Cosmetic ingredients in the United States are not subject to FDA premarket approval, and acetyl hexapeptide does not appear in any of the three categories of FDA's 503A bulk drug substances list as updated May 14, 2026 9. The Expert Panel for Cosmetic Ingredient Safety concluded in 2025 that acetyl hexapeptide-8 amide raised no safety concern in cosmetics at concentrations up to 0.005% as currently used, and that available data are insufficient to reach that conclusion above that concentration 1.
United States (FDA)
Marketed as a cosmetic ingredient rather than a drug. Cosmetic ingredients in the United States are not subject to FDA premarket approval, and acetyl hexapeptide does not appear in any of the three categories of FDA's 503A bulk drug substances list as updated May 14, 2026 9. Absence from drug databases is therefore expected and says nothing about efficacy.
Sport (WADA)
Not named individually in the sources reviewed; S0 covers substances without governmental approval for human therapeutic use, prohibited at all times 10. Cosmetic status does not by itself place a substance outside the List, since the List is organised by substance rather than product category; athletes should seek a ruling from their anti-doping organisation.

Status varies by country and changes over time. How we describe regulatory status.

Quality and testing notes

A certificate of analysis should state the exact sequence and both terminal modifications (N-acetyl and C-terminal amide), since naming in this family is inconsistent: PubChem lists acetyl hexapeptide-3 and acetyl hexapeptide-8 as synonyms for the same entry, and the longer acetyl octapeptide-3 (SNAP-8) is a different molecule whose data do not transfer [8]. Expect identity by mass spectrometry against the calculated mass for C34H60N14O12S (Ac-EEMQRR-NH2) (average mass about 889 Da), purity by reverse-phase HPLC with the trace and integration shown, net peptide content separate from gross weight, counter-ion identity (acetate or trifluoroacetate) and water content. The sequence contains methionine, which oxidises readily to the sulfoxide, so oxidation-related impurities should be reported. For a cosmetic raw material, microbial limits and heavy-metal testing are also conventional.

How purity testing works · Reading a certificate of analysis

Check a Argireline certificate of analysis against its expected mass (889 Da)

Storage and handling

General research-context handling only. Lyophilised peptides of this type are generally kept dry, cool and protected from light, moisture and oxidising conditions, with methionine-containing sequences particularly oxidation-sensitive; aqueous solutions are treated as short-lived. Finished cosmetic formulations follow the manufacturer's own stability data. Defer to supplier documentation for the specific lot.

Frequently asked questions

Is Argireline the same as acetyl hexapeptide-8?
Yes. Argireline is the trade name; the ingredient name is acetyl hexapeptide-8, also listed as acetyl hexapeptide-3 8. It is a different and shorter molecule than acetyl octapeptide-3 (SNAP-8), and data on one do not transfer to the other 8.
Does it work like botulinum toxin?
That is the marketing premise, based on sequence resemblance to SNAP-25. A 2025 review concluded that whether the peptide reaches neuromuscular junctions after topical application is uncertain and the mechanism incompletely understood, and a rat injection study found no detectable tissue-level effect 2,5,6.
What did the double-blind split-face study find?
In a double-blind split-face study in 19 women, the side treated with the peptide-containing serum did not differ significantly from the side treated with the same serum without it, and the author concluded the effect was not demonstrated 3.
Has any randomized trial reported a change?
A three-arm randomized trial in 21 women reported improvement in several subjects over eight weeks and judged the palmitoyl pentapeptide-4 arm to show more change than the acetyl hexapeptide-3 arm; the authors described the study as an initial one needing a larger sample 4.
Can a peptide this size get into the skin?
Penetration is the main open question. The 2025 review identifies the peptide's hydrophilicity and size as limiting passage through the stratum corneum, which is why emulsion and microneedle strategies are studied 2,11.
What has the Cosmetic Ingredient Review panel concluded?
The Cosmetic Ingredient Review Expert Panel concluded in 2025 that acetyl hexapeptide-8 amide raised no safety concern in cosmetics at concentrations up to 0.005% in present practices of use, and that available data are insufficient to make that determination at higher concentrations 1.
Is it FDA-approved?
No. It is a cosmetic ingredient, and cosmetic ingredients do not undergo FDA premarket approval in the United States; it also does not appear in any category of FDA's 503A bulk drug substances list 9.
Is it banned in sport?
It is not named individually in the sources reviewed. S0 covers any pharmacological substance with no current governmental approval for human therapeutic use, prohibited at all times, so athletes should ask their anti-doping organisation 10.

Latest indexed research

Search all studies on Argireline (PubMed, Europe PMC, ClinicalTrials.gov)

Listed by publication type from the index record. Inclusion is not an endorsement; open the source to read the findings.

Revision history

Meaningful changes to this entry, with dates and sources. Last reviewed Oct 24, 2026. Typo and layout fixes are not listed.

  • New section· entryOct 24, 2026

    New research reference added: Argireline.

References

  1. Safety Assessment of Acetyl Hexapeptide-8 Amide as Used in Cosmetics Int J Toxicol. 2025
  2. Acetyl Hexapeptide-8 in Cosmeceuticals - A Review of Skin Permeability and Efficacy Int J Mol Sci. 2025
  3. Investigating the effects of Argireline in a skin serum containing hyaluronic acids on skin surface wrinkles using the Visia Complexion Analysis camera system for objective skin analysis GMS Interdiscip Plast Reconstr Surg DGPW. 2023
  4. Double-blind, Randomized Trial on the Effectiveness of Acetylhexapeptide-3 Cream and Palmitoyl Pentapeptide-4 Cream for Crow's Feet J Clin Aesthet Dermatol. 2023
  5. Effects of Botulinum Toxin Type A and Argireline on Dermal Collagen Remodeling and Skin Biology in a Flap Model Aesthetic Plast Surg. 2026
  6. Acetyl Hexapeptide-8 as a Topical Alternative to Botulinum Toxin: A Review of the Literature J Drugs Dermatol. 2025
  7. Public Interest in Acetyl Hexapeptide-8: Longitudinal Analysis JMIR Dermatol. 2024
  8. Acetyl hexapeptide-3 / Acetyl Hexapeptide-8 (CID 71587772) PubChem. 2026
  9. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026); no entry for acetyl hexapeptide or argireline in any of the three categories FDA. 2026
  10. International Standard: Prohibited List 2026 World Anti-Doping Agency. 2026
  11. Dermal Stability and In Vitro Skin Permeation of Collagen Pentapeptides (KTTKS and palmitoyl-KTTKS) Biomol Ther (Seoul). 2014
  12. The effect of a serum containing acetyl hexapeptide-8, dipeptide diaminobutyroyl benzylamide diacetate and gluconolactone on skin biomarkers, wrinkles and skin texture: Ex vivo and clinical studies Int J Cosmet Sci. 2026

Last reviewed October 24, 2026 by the Amiravo editorial team.

Read our editorial policy · Report an error on this page

Need the math?

Laboratory arithmetic with every formula shown.

For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement. This page is educational and is not medical advice.

Unbranded reference vial illustrating Argireline; not an actual product

Unbranded reference image. Amiravo does not produce, supply or sell this compound.

Specifications

Molecular weight
889 g/mol
CAS number
616204-22-9
FDA UNII
L4EL31FWIL
DrugBank
DB11709
Sequence
Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2
Type
Single compound

Chemical identifiers are shown only when verified against PubChem.

Research stats

How much has been published, not how good it is.

PubMed records
47
Indexed as human research
29
Animal-only research
3
Randomized controlled trials
3
Registered trials
7
Trials with posted results
2
2006: 02007: 12008: 02009: 02010: 02011: 02012: 12013: 42014: 62015: 22016: 02017: 12018: 12019: 12020: 42021: 62022: 12023: 32024: 52025: 92026: 820062026
PubMed records per year (current year is partial).

Counts from title/abstract searches of PubMed, ClinicalTrials.gov, openFDA and NIH RePORTER, checked 2026-10-24. Names shared with other substances can inflate counts. FAERS reports are spontaneous and do not establish cause. Funding shows interest, not evidence. Method

Follow Argireline

See every new citation, evidence-grade or status change and correction in My Research, with optional email alerts. Free account.